Clinical Trial Update: MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating maintenance of efficacy and safety after switching to a long-acting injectable aripiprazole from oral atypical antipsychotics in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Aripiprazole long-acting injectable (aripiprazole)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Schizophrenia, Antipsychotics | Phase 4 | Status: COMPLETED